Read More »"/> Read More »"/>
 
Tag: drug regulation
Cut Regulations and Get COVID-19 Drugs to Patients

As the coronavirus pandemic continues to ravage the U.S. healthcare system, many healthcare professionals are struggling to find enough medical supplies to treat patients and to avoid becoming infected themselves. A recent New York Post article finds nurses working in a New York City hospital resorted to covering themselves with garbage bags because the…
Read More »

FDA’s Approval of Generic Daraprim Offers Lessons on Drugs Prices

In 2015, Turning Pharmaceuticals CEO Martin Shkreli increased the price of the drug Daraprim nearly 5,000 percent from $13.50 to $750 per pill. The price hike generated widespread outrage, earning Shkreli the moniker “Pharma Boy” and the designation, “pharmaceutical greed villain.” Daraprim became “the poster child for the issue of high drug prices.”

Politicians Still Misunderstand High Insulin Prices

In 2015, the Centers for Disease Control ranked diabetes seventh among the leading causes of death in the United States. If current trends continue, skyrocketing death rates and other serious consequences of poorly managed diabetes will continue. Managing diabetes is challenging, often requiring strict dieting, regular exercise, and taking a variety of medications. For…
Read More »

Robert Klein, Davy Crockett, and the Quest for Another $5.5 Billion for Stem Cells

As this column has often noted, the 2004 ballot measure Proposition 71, the $3 billion California Stem Cell Research and Cures Act, promised life-saving cures for Alzheimer’s, Parkinson’s and other diseases, plus a steady stream of royalties for state coffers. In 2020, a ballpark estimate for the promised cures and therapies is zero, and…
Read More »

Will FDA Approve Biogen’s Promising New Treatment for Alzheimer’s?

We’re only a few weeks into the new year, and the Food and Drug Administration will soon make a decision that will affect pharmaceutical regulation for decades. Last year, after failing an FDA-required futility test, Biogen abandoned its efforts to develop an Alzheimer’s treatment named aducanumab. However, after conducting an analysis using an expanded…
Read More »

Breakthrough Alzheimer’s Drug Puts FDA’s Drug-Approval Process into Question

After many successful years as a corporate manager, Roger retired in his late sixties to spend more time with family. Three years into retirement, his once energetic and outgoing demeanor deteriorated, and he no longer found interest in things he once enjoyed. Concerned, his physician referred him to a psychiatrist. During his evaluation, Roger…
Read More »

Misdiagnosing Right-to-try Laws

Right-to-try laws only apply to terminally ill patients who have exhausted all other options.

  • Catalyst
  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org